ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER).
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
| Metabolism | Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools. |
| Excretion | ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water. |
| Half-life | Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function. |
| Protein binding | None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution. |
| Volume of Distribution | Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration). |
| Bioavailability | 100% intravenous; not administered by other routes. |
| Onset of Action | Immediate upon intravenous infusion; clinical effect (electrolyte and fluid replacement) begins within minutes. |
| Duration of Action | Duration depends on infusion rate and renal function; typically 1-2 hours for glucose effect (insulin response), electrolytes persist until redistributed/excreted. Continuous infusion required for maintenance. |
Intravenous infusion; typical adult dose is 1000-2000 mL per day (30 mL/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
| Dosage form | INJECTABLE |
| Renal impairment | In renal impairment (eGFR < 30 mL/min/1.73m²), reduce total volume to 500-1000 mL/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload. |
| Liver impairment | No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 mL/day. |
| Pediatric use | Weight-based: 20-50 mL/kg/day for maintenance; neonates and infants: 100-150 mL/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 mL/kg/hour for neonates. |
| Geriatric use | Start with lower volumes (500-1000 mL/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume. |
| Teratogenic Risk | ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported. |
■ FDA Black Box Warning
Not applicable; no FDA boxed warning exists for this product.
| Serious Effects |
["Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions."]
| Precautions | ["Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, glucose, and fluid balance. Assess for signs of fluid overload (e.g., edema, pulmonary congestion). In pregnancy, monitor fetal heart rate and uterine activity during infusion. Monitor maternal blood glucose, especially in gestational diabetes or when dextrose load is high. Assess for maternal hypoglycemia after discontinuation. |
| Fertility Effects | No known adverse effects on fertility. Dextrose and electrolyte solutions are standard components of maintenance therapy; no impairment of reproductive function has been reported. |